R Squared Ltd Invests $74,000 in Fulgent Genetics, Inc. (NASDAQ:FLGT)

R Squared Ltd purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,030 shares of the company’s stock, valued at approximately $74,000.

Several other hedge funds have also bought and sold shares of the business. Point72 Asset Management L.P. bought a new position in shares of Fulgent Genetics during the third quarter valued at approximately $5,854,000. Millennium Management LLC increased its position in Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock valued at $18,813,000 after buying an additional 244,981 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Fulgent Genetics by 113.2% during the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after buying an additional 179,477 shares during the last quarter. Invenomic Capital Management LP grew its stake in shares of Fulgent Genetics by 98.9% in the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after acquiring an additional 124,185 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Fulgent Genetics by 22.6% during the third quarter. Barclays PLC now owns 174,855 shares of the company’s stock valued at $3,800,000 after acquiring an additional 32,250 shares in the last quarter. Institutional investors own 48.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Piper Sandler reduced their price target on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th.

Insiders Place Their Bets

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,227 shares of Fulgent Genetics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the completion of the sale, the chief executive officer now owns 703,711 shares of the company’s stock, valued at approximately $12,849,762.86. The trade was a 0.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 3,413 shares of company stock valued at $62,321. 31.76% of the stock is owned by insiders.

Fulgent Genetics Trading Down 2.1 %

Fulgent Genetics stock opened at $16.64 on Friday. Fulgent Genetics, Inc. has a 12 month low of $16.36 and a 12 month high of $26.36. The stock has a fifty day simple moving average of $18.47 and a two-hundred day simple moving average of $20.48. The firm has a market cap of $509.02 million, a price-to-earnings ratio of -3.01 and a beta of 1.40.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.